课题基金 / 基金详情

DNA methylation as a diagnostic marker in AML

DNA methylation as a diagnostic marker in AML
DNA 甲基化作为 AML 的诊断标志物
批准号:
6998912
负责人:
CHRISTOPH PLASS
金额:
$28.84万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-01-01 至 2007-12-31

项目摘要

项目成果

CHRISTOPH PLASS的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by applicant): Aberrant DNA methylation in the promoter region of genes is found in a variety of human cancers and is thought to be associated with gene silencing. Restriction Landmark Genomic Scanning (RLGS) is currently the only technique that allows the scanning of thousands of promoter sequences for aberrant DNA methylation in human cancer. Aberrant DNA methylation was recently shown to be a major contributor and an early event in tumorigenesis, especially in the development of acute myeloid leukemia (AML). In this application we propose to investigate the role of DNA methylation in AML with special emphasis on clinical correlates. The samples that will be used for this study will come from the CALGB Leukemia Tissue Bank. Our hypothesis is that epigenetic changes (DNA methylation) are equally important as genetic alterations in leukemogenesis but have been underestimated in its extend. Since methylation changes could affect the transcription of genes it is likely that these epigenetic differences contribute to the molecular defects that underlie normal karyotype AML. Subsequently, aberrantly methylated targets can be used to identify novel diagnostic or prognostic biomarkers in AML. To test this hypothesis our specific aims are (1) to study methylation profiles in a subset of normal karyotype AML with blast counts >50 percent. (2) Rigorous statistical and bioinformatical analysis will identify diagnosis and relapse specific methylation events, candidate subclass predicting methylation events and finally methylation targets that correlate with clinical data such as duration of complete remission. (3) A small subset of highly informative methylation targets will be studied in detail by bisulfite sequencing. MS-PCR tests will be developed that allow (4) screening of larger patient samples. Statistical analysis will be performed to determine the value of a methylation event as a diagnostic biomarker or as a marker with predictive value.
期刊论文(7)
专著(0)
科研奖励(0)
会议论文
Epigenetics in acute myeloid leukemia.
急性髓样白血病的表观遗传学。
DOI: 10.1053/j.seminoncol.2008.04.008
发表时间: 2008-08
期刊: Seminars in oncology
影响因子: 4
作者: [Plass C, Oakes C, Blum W, Marcucci G]
通讯作者: Marcucci G
Genome-wide analysis of DNA methylation changes in human malignancies.
人类恶性肿瘤 DNA 甲基化变化的全基因组分析。
DOI: 10.1007/3-540-31181-5_9
发表时间: 2006
期刊: Current topics in microbiology and immunology
影响因子: --
作者: [Plass,C, Smiraglia,DJ]
通讯作者: Smiraglia,DJ
Genotyping and Sequencing
  • 批准号:
    7613088
  • 项目类别:
  • 资助金额:
    $9.16万
  • 财政年份:
    2005
  • 负责人:
    CHRISTOPH PLASS
  • 依托单位:
Identification of Methylated Genes in Chronic Lymphocytic Leukemia
  • 批准号:
    6986001
  • 项目类别:
  • 资助金额:
    $21.76万
  • 财政年份:
    2005
  • 负责人:
    CHRISTOPH PLASS
  • 依托单位:
DNA methylation as a diagnostic marker in AML
  • 批准号:
    6417420
  • 项目类别:
  • 资助金额:
    $29.49万
  • 财政年份:
    2002
  • 负责人:
    CHRISTOPH PLASS
  • 依托单位:
DNA methylation as a diagnostic marker in AML
  • 批准号:
    6620434
  • 项目类别:
  • 资助金额:
    $29.54万
  • 财政年份:
    2002
  • 负责人:
    CHRISTOPH PLASS
  • 依托单位:
海外基金